All In Biotech

Drug Trial Radar · NCT02567656

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Sep 2015

Primary completion

Mar 2018

Study completion Dec 10, 2018

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Oct 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Conditions

  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell, Cutaneous

Interventions

  • RP6530Drug

    Tablet starting at 200 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of RP6530Time frame: 28 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Chao Family Comprehensive Cancer Center University of California Irvine

    Orange, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.